Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parameters of endothelial function after anti-TNF-therapy (Etanercept, Certolizumab, Infliximab,Adalimumab and Infliximab) or methotrexate in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

Trial Profile

Parameters of endothelial function after anti-TNF-therapy (Etanercept, Certolizumab, Infliximab,Adalimumab and Infliximab) or methotrexate in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Methotrexate
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jul 2018 New trial record
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top